UCB has completed its $1.9 billion acquisition of biopharmaceutical company Zogenix. UCB paid $26 per share and will pay another $2 per share, subject to the approval of FINTEPLA, a drug to treat Lennox-Gasto syndrome, by Dec. 31, 2023.
UCB has completed its $1.9 billion acquisition of biopharmaceutical company Zogenix. UCB paid $26 per share and will pay another $2 per share, subject to the approval of FINTEPLA, a drug to treat Lennox-Gasto syndrome, by Dec. 31, 2023. 
English (US) 